Cover Image
市場調查報告書

全球抗菌藥市場:2017年∼2027年

Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others

出版商 Visiongain Ltd 商品編碼 226947
出版日期 內容資訊 英文 304 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗菌藥市場:2017年∼2027年 Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others
出版日期: 2017年03月13日 內容資訊: 英文 304 Pages
簡介

全球抗菌藥市場,預計從2016年的417億6000萬美元,2021年擴大到445億4000萬美元。

本報告提供全球抗菌藥市場相關調查分析,市場預測,次市場的預測,主要的上市藥的收益預測,主要的先進、新興各國和各地市場收益預測,研發產品線等系統性資訊。

第1章 報告概要

第2章 所謂抗菌藥

  • 細菌感染的種類
  • 引起感染疾病的主要細菌
  • 一般細菌感染的發病率和死亡率
  • 感染疾病的治療
    • 抗菌藥的發展歷史
    • 作用機制
    • 主要藥物類別
    • 抗生素抗藥性

第3章 抗菌藥:全球市場

  • 抗菌藥收益漲到極限
  • 抗菌劑:市場區隔
  • 抗菌藥市場預測:氟喹諾酮類藥物的收益減少
  • 市場的推動因素與阻礙因素
  • 學名藥的衰退和處方箋管理抑制市場成長
  • Pfizer是領導者
  • 分散市場更分散

第4章 頭孢菌素市場預測

  • 頭孢菌素市場現狀:缺乏主導品牌
    • 後期階段的頭孢菌素今後市場佔有率將擴大
    • Basilea、Merck、Actavis、AstraZeneca先導
    • 推動因素、阻礙因素
    • 沒有市場優先權的頭孢菌素
    • 新的頭孢菌素的強力開發平台
    • Rocephin (Roche) :美國的淋病的唯一治療方法
    • Sulperazon:印度的呼吸系統感染疾病 (RTI) 、泌尿道感染 (UTI)的代表性的治療方法
    • Zinnat/Ceftin:GSK的既成的頭孢菌素
    • Meiact:多樣的社區性感染症用的抗菌藥
    • Flomox:鹽野義製藥的第三代頭孢菌素
    • Zinforo/Teflaro (Ceftaroline Fosamil) :第一個第5代頭孢菌素
    • 作為Zeftera (Ceftobiprole) :歐洲肺炎治療藥認證
    • CXA-201 (Ceftrolozane-Tazobactam) :下個重量級抗菌藥
    • CAZ-AVI (Ceftazidime-Avibactam) :已通過核准

第5章 青霉素市場預測

  • 學名藥和Augmentin獨佔市場
  • 青霉素的市場佔有率:Augmentin今後10年喪失獨佔地位
  • 青霉素的市場規模預測
  • 推動因素、阻礙因素
  • Augmentin:面臨與學名藥的競爭的暢銷藥物
  • Zosyn/Tazocin (Piperacillin-Tazobactam) :肺炎的治療藥
  • Unasyn:革蘭氏陰性菌/陽性菌用抗菌藥
  • Amoxil (Amoxicillin) :歷史性的抗菌藥品牌
  • Amoxicillin的學名藥
  • Clavulanic Acid:Amoxicillin的學名藥

第6章 Fluoroquinolones 市場預測

  • Fluoroquinolones 市場
  • 市場佔有率的變化
  • Fluoroquinolones 抗菌藥:市場預測
  • 市場趨勢
  • 市場預測
  • Avelox
  • Cravit、Levaquin
  • Vigamox
  • Cirpodex、Cipro:Ciprofloxacin的2種調劑藥
  • Geninax
  • Delafloxacin

第7章 大環內酯類市場預測

  • 大環內酯類市場
  • 市場佔有率的變化
  • 大環內酯類抗菌藥:市場預測
  • 市場趨勢
  • Biaxin/Clarith
  • Zithromax
  • Dalacin
  • Dificid
  • Solithromycin

第8章 碳青霉烯類市場預測

  • 碳青霉烯類市場
  • 市場佔有率的變化
  • 碳青霉烯類抗菌藥:市場預測
  • 市場趨勢
  • Merrem/Meropenem
  • Primaxin
  • Invanz
  • Doribax

第9章 其他抗菌藥市場預測

  • 其他藥劑級的市場
  • 市場佔有率的變化
  • 其他抗菌藥:市場預測
  • 市場趨勢
  • Zyvox:代表性抗菌藥
  • Cubicin:ABSSSI的代表性品牌
  • Tygacil:受許多適應症認證的四環黴素
  • TOBI/TOBI Podhaler:囊腫纖維化的代表性吸入器
  • Solodyn:嚴重痤瘡的治療藥
  • Vibativ:新的Lipoglycopeptide的受限制未來性
  • Sirturo:多重抗藥性TB(結核的)的新選擇
  • Tedizolid:成為繼Zyvox的代表性醫藥品嗎?
  • Oritavancin:新的附PK特徵的抗菌藥
  • Dalbavancin:適應症市場上的激烈競爭
  • Surotomycin:梭狀桿菌 (C. difficile) 治療藥
  • Nemonoxacin:台灣的全球市場取向抗菌藥

第10章 主要國家市場

  • 美國和中國獨佔市場
  • 美國有平均以上的市場成長:各地區預測
  • 預計中國的市場佔有率停頓,巴西和印度的市場佔有率擴大
  • 感染疾病的發病率:各國
  • 抗菌藥的消費:各國
  • 美國的抗菌藥市場
  • EU:全球第二大市場
  • 日本:依然是全球第4位
  • 韓國:抗菌藥的利用水準今後仍高嗎?
  • 金磚四國:預計更擴大
  • 中國:抗菌藥的過度利用造成的市場擴大
  • 印度:預測今後10年擴大50%
  • 巴西:預定2倍增加
  • 俄羅斯:TB流行的市場成長預測

第11章 抗菌藥的研發產品線檢驗

  • 革蘭氏陽性 vs.革蘭氏陰性
  • 小分子藥獨佔的開發平台
  • 第三階段的主要候補藥
  • 第二階段的主要抗菌劑候補藥
  • 吸入抗菌藥
  • 生技藥品:最新的治療藥
  • 其他級

第12章 抗菌藥產業、市場定性分析

  • SWOT分析
  • STEP分析
  • 市場的成熟度與強力需求的預定
  • 全球感染疾病的高盛行率
  • 全球抗菌藥的需求
  • 感染疾病的動物模式:與其他治療領域相比有更高的可預測性
  • 飽和市場的進入
  • 優於學名藥等

第13章 抗菌藥市場:結論

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0175

The global antibacterial drugs market is expected to grow at a CAGR of 1.3% in the first half of the forecast period and a CAGR of 3.1% in the second half of the forecast period. The market is estimated at $41.76bn in 2016 and $44.54bn in 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 304-page report you will receive 124 tables and 97 figures - all unavailable elsewhere.

The 304-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Antibacterial Drugs Market forecasts from 2017-2027
  • Revenue forecasts for the 6 leading submarkets from 2017-2027:
    • Cephalosporins
    • Penicillins
    • Fluoroquinolones
    • Macrolides
    • Carbapenems
    • Others
  • Revenue forecasts for the 43 leading marketed antibacterial drugs from 2017-2027:
    • Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
    • Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
    • Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
    • Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
    • Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
    • Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin
  • Revenue forecasts for the leading developed and emerging national and regional markets. Markets forecasted in this report are the following:
    • The US
    • The EU: France, Germany, Italy, Spain, the UK, and others
    • Japan
    • The BRIC countries: Brazil, Russia, India, China
    • South Korea
    • The Rest of the World
  • Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market
  • Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development - see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Visiongain's study is intended for anyone requiring commercial analyses for the Global Antibacterial Drugs Market. You find data, trends and predictions.

Buy our report today Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analysis
  • 1.5. Who is This Study For?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports

2. Introduction to Antibacterial Drugs

  • 2.1. Types of Bacterial Infection
  • 2.2. Main Bacteria Causing Infections in Human Beings
  • 2.3. Incidence and Mortality Profiles for Common Bacterial Infection
  • 2.4. Treating Infections
    • 2.4.1. The History of Antibacterial Drug Development
    • 2.4.2. Mechanisms of Action
    • 2.4.3. Leading Classes of Antibacterial Medicines
      • 2.4.3.1. Cephalosporins
      • 2.4.3.2. Penicillins
      • 2.4.3.3. Carbapenems
      • 2.4.3.4. Fluoroquinolones
      • 2.4.3.5. Macrolides
    • 2.4.4. Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market 2017-2027

  • 3.1. Antibacterial Drugs Revenues Plateau between 2011 and 2016
  • 3.2. Antibacterial Agents - Market Segmentation
  • 3.3. Antibacterial Drugs Market Forecast 2017-2027: Decline in Revenues for Fluoroquinolones
  • 3.4. Drivers and Restraints in the Antibacterial Drugs Market, 2017-2027
  • 3.5. Generic Erosion and Prescription Control Will Limit Market Growth
  • 3.6. Changes in that Industry Sector's Market Shares, 2017-2027
  • 3.7. Pfizer is the Leader in the Antibacterial Drugs Market, 2016
  • 3.8. Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast 2017-2027

  • 4.1. Cephalosporins Market 2016-No Dominant Brands
    • 4.1.1. Late-Stage Cephalosporins to Gain Market Share Between 2017 and 2027
    • 4.1.2. Basilea, Merck, Actavis and AstraZeneca to Lead the Cephalosporins Market Between 2017 and 2027
    • 4.1.3. Drivers and Restraints on the Cephalosporins Market, 2017-2027
    • 4.1.4. Cephalosporins Lack Market Exclusivity
    • 4.1.5. Strong Pipeline for Novel Cephalosporins
    • 4.1.6. Rocephin (Roche)-The Only Treatment for Gonorrhoea in the US
      • 4.1.6.1. Off Patent but Still Effective
      • 4.1.6.2. Declining Revenues Owing to Competition - Forecast 2017-2027
    • 4.1.7. Sulperazon-India's Leading Treatment for RTIs and UTIs
      • 4.1.7.1. Continued Growth in the Emerging Markets, Revenue Forecast 2017-2027
    • 4.1.8. Zinnat/Ceftin-GSK's Established Cephalosporin
      • 4.1.8.1. Continued Decline in Revenue - Forecast 2017-2027
    • 4.1.9. Meiact-A Broad Range Community Antibiotic
      • 4.1.9.1. Spectracef Sales in the US Leads to Pass the Product
      • 4.1.9.2. Competition in Japan to Hinder Growth-Revenue Forecast 2017-2027
    • 4.1.10. Flomox - Shionogi's Third-Generation Cephalosporin
      • 4.1.10.1. Patent Issues and Litigation
      • 4.1.10.2. Genericization and Safety to Restrict Sales - Forecast 2017-2027
    • 4.1.11. Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
      • 4.1.11.1. Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2017-2027
    • 4.1.12. Zeftera (ceftobiprole): Approved for Pneumonia in Europe
      • 4.1.12.1. Future Sales Dictated by US Approval - Revenue Forecast 2017-2027
    • 4.1.13. CXA-201. (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
      • 4.1.13.1. Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast 2017-2027
    • 4.1.14. CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
      • 4.1.14.1. Competition from CXA-201 to Limit Sales - Forecast 2017-2027

5. Penicillins Market Forecast 2017-2027

  • 5.1. Generics and Augmentin Dominate the Penicillins Market in 2016
  • 5.2. Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin Drugs, 2017-2027
  • 5.3. Penicillin Antibacterial Drugs: Market Forecast 2017-2027
  • 5.4. Drivers and Restraints for the Penicillin Market 2017-2027
  • 5.5. Augmentin-Blockbuster Facing Generic Competition
    • 5.5.1. Augmentin-Challenges in Some Countries
    • 5.5.2. Stable Revenues Regardless of Generic Competition
    • 5.5.3. Revenue Forecast 2017-2027
  • 5.6. Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
    • 5.6.1. Patent Expiry and Revenue Extension for Pfizer
    • 5.6.2. Historic and Current Revenue Performance
    • 5.6.3. Revenue Forecast 2017-2027
  • 5.7. Unasyn-Gram-negative and Positive Antibiotic
    • 5.7.1. Falling Revenues - Forecast 2017-2027
  • 5.8. Amoxil (Amoxicillin)-A Historic Antibacterial Brand
    • 5.8.1. Marginal Decline in Revenue - Forecast 2017-2027
  • 5.9. Generic Amoxicillin
    • 5.9.1. Revenue Forecast 2017-2027
  • 5.10. Generic Amoxicillin-Clavulanic Acid
    • 5.10.1. Revenue Forecast 2017-2027

6. Fluoroquinolone Market Forecast 2017-2027

  • 6.1. The Fluoroquinolone Market 2016
  • 6.2. Changing Market Share for Fluoroquinolone Antibacterial Drugs, 2017-2027
  • 6.3. Fluoroquinolone Antibacterial Drugs: Market Forecast 2017-2027
  • 6.4. Trends in the Fluoroquinolone Market
    • 6.4.1. Safety Fears for Fluoroquinolones
    • 6.4.2. Avelox Patent Cliff
    • 6.4.3. Inhaled Fluoroquinolone Formulations
  • 6.5. Fluoroquinolone Market Forecast 2017-2027
  • 6.6. Avelox
    • 6.6.1. Safety Profile Hampers Sales
    • 6.6.2. Generic Competition
    • 6.6.3. Revenue Forecast 2017-2027
  • 6.7. Cravit and Levaquin
    • 6.7.1. Generic Competition Affecting Revenue Worldwide
    • 6.7.2. Lifecycle Management for Cravit and Levaquin
    • 6.7.3. Revenue Forecast 2017-2027
  • 6.8. Vigamox
    • 6.8.1. Branded and Generic Challenges 2011-2016
    • 6.8.2. Moxeza: A Next-Generation Form of Vigamox
    • 6.8.3. Revenue Forecast 2017-2027
  • 6.9. Ciprodex and Cipro-Two Preparations of Ciprofloxacin
    • 6.9.1. Ciprodex: A Second-Generation Ophthalmic Antibiotic
  • 6.9.1.1. Revenue Forecast 2017-2027
    • 6.9.2. Cipro Revenue Forecast 2017-2027: Continued Generic Erosion
  • 6.10. Geninax
    • 6.10.1. Revenue Forecast 2017-2027
  • 6.11. Delafloxacin
    • 6.11.1. Revenue Forecast 2017-2027

7. Macrolide Market Forecast 2017-2027

  • 7.1. Macrolide Market in 2016
  • 7.2. Changing Market Share for Macrolides, 2017-2027
  • 7.3. Macrolide Antibacterial Drugs: Market Forecast 2017-2027
  • 7.4. Trends in the Macrolide Market
  • 7.5. Biaxin/Clarith
    • 7.5.1. Past Revenue 2011-2015
    • 7.5.2. Lifecycle Management for Continued Market Presence
    • 7.5.3. Revenue Forecast 2017-2027
  • 7.6. Zithromax
    • 7.6.1. Concerns Over Safety and Marketing in the US
    • 7.6.2. Effectiveness in Drug-Resistant Strains
    • 7.6.3. Revenue Forecast 2017-2027
  • 7.7. Dalacin
    • 7.7.1. Revenue Forecast 2017-2027
  • 7.8. Dificid
    • 7.8.1. Rapid Uptake Slowed by High Cost
    • 7.8.2. New Approvals and Expanded Indications
    • 7.8.3. Revenue Forecast 2017-2027
  • 7.9. Solithromycin
    • 7.9.1. Revenue Forecast 2017-2027

8. Carbapenem Market Forecast 2017-2027

  • 8.1. Carbapenem Market 2016
  • 8.2. Changing Market Share for Carbapenems, 2017-2027
  • 8.3. Carbapenem Antibacterial Drugs: Market Forecast 2017-2027
  • 8.4. Trends in the Carbapenem Market
    • 8.4.1. Rising Prevalence of Carbapenemases and β-Lactamases
    • 8.4.2. No New Carbapenems in Late-Stage Trials
  • 8.5. Merrem/Meropenem
    • 8.5.1. Generics Affecting Revenue Worldwide
    • 8.5.2. Revenue Forecast 2017-2027
  • 8.6. Primaxin
    • 8.6.1. Combination Therapy for Lifecycle Management
    • 8.6.2. Historic and Current Revenues
    • 8.6.3. Revenue Forecast 2017-2027
  • 8.7. Invanz
    • 8.7.1. Revenue Forecast 2017-2027
  • 8.8. Doribax
    • 8.8.1. Doribax in HAP and VAP
    • 8.8.2. Lifecycle Management in Japan and the Rest of the World
    • 8.8.3. Revenue Forecast 2017-2027

9. Other Antibacterial Drugs Forecast 2017-2027

  • 9.1. The Market for Other Classes of Antibacterial Drugs
  • 9.2. Changing Market Share for Fluoroquinolone Antibacterials 2017-2027
  • 9.3. Other Antibacterials: Market Forecast 2017-2027
  • 9.4. Trends in the Other Classes of Antibacterial Drugs
    • 9.4.1. New Oxazolidinones Will Drive Growth
    • 9.4.2. New Drug Classes to Drive Submarket Growth to 2027
  • 9.5. Zyvox-The Market Leading Antibacterial
    • 9.5.1. MRSA Activity Driving Revenue Growth
    • 9.5.2. Promise in Tuberculosis and Anthrax
    • 9.5.3. Patents, Litigation, and Competition-When and Who Will Produce Generic Linezolid?
    • 9.5.4. Flat Growth to Patent Expiry, Revenue Forecast 2017-2027
  • 9.6. Cubicin-The Leading Brand for ABSSSIs
    • 9.6.1. Revenue Boosted by Approvals Worldwide
    • 9.6.2. Patents, Litigation and Deals-How Long Will Market Exclusivity Last?
    • 9.6.3. Sustained Growth through to 2021, Revenue Forecast 2017-2027
  • 9.7. Tygacil-A Tetracycline with Many Approved Indications
    • 9.7.1. Concerns Limiting Revenue Potential
    • 9.7.2. Competition from Other Therapies Restricts Growth: Revenue Forecast 2017-2027
  • 9.8. TOBI/TOBI Podhaler-The Market Leading Inhaler for Cystic Fibrosis
    • 9.8.1. Historic and Current Revenue Performance
    • 9.8.2. Approvals and Launches in New Markets to Drive Revenue Growth
    • 9.8.3. Competition to Limit Long-term Growth, Revenue Forecast 2017-2027
  • 9.9. Solodyn-A Treatment for Severe Acne
    • 9.9.1. Generic Competition and Lifecycle Management
    • 9.9.2. Limited Potential for Dermatology, Revenue Forecast 2017-2027
  • 9.10. Vibativ-Limited Potential for Novel Lipoglycopeptide
    • 9.10.1. Astellas Ends its Collaboration with Theravance
    • 9.10.2. Limited HAP Label in the US - Revenue Forecast 2017-2027
  • 9.11. Sirturo-A New Option for Multi-Drug Resistant TB
    • 9.11.1. Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2017-2027
  • 9.12. Tedizolid-Market Leading Follow-on to Zyvox?
    • 9.12.1. Competition Increasing: Revenue Forecast 2017-2027
  • 9.13. Oritavancin-An Antibiotic with a Novel PK Profile
    • 9.13.1. Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2017-2027
  • 9.14. Dalbavancin-Competing in a Crowded Indication
    • 9.14.1. Sustained Growth Over the Coming 10 Years, Revenue Forecast 2017-2027
  • 9.15. Surotomycin -Treatment for C. difficile
    • 9.15.1. Delayed Launch to Limit Potential, Revenue Forecast 2017-2027
  • 9.16. Nemonoxacin-Taiwan's Global Antibacterial Drug
    • 9.16.1. Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2017-2027

10. The Leading National Markets 2017-2027

  • 10.1. US and China Dominate the Global Antibacterial Market, But for Different Reasons
  • 10.2. Above-Average Growth in US: Regional Forecasts 2017-2027
  • 10.3. China to Slump in Market Share, While Brazil and India Push on
  • 10.4. Incidence of Infection by Country, 2016
    • 10.4.1. Incidence of Pneumonia in National Markets-Pneumonia Predominant in America
    • 10.4.2. Incidence of Community Acquired Urinary Tract Infections in National Markets-High Incidence Rates in the UK, US and Spain
    • 10.4.3. Incidence of Bacterial Skin and Skin Structure Infections in National Markets-High Potential in the US
    • 10.4.4. Incidence of Upper Respiratory Tract Infections in National Markets-Europe Leads the Way
  • 10.5. Antibacterial Drug Consumption by Country, 2016
    • 10.5.1. Antibacterial Drug Consumption in the Major National Markets
    • 10.5.2. Antibacterial Drug Consumption in Some Other National Markets
  • 10.6. The Antibacterials Market in the US
    • 10.6.1. Continued Dominance of the US Market
  • 10.7. The European Union Forms Second Largest Regional Market
    • 10.7.1. Marginal Expansion in Antibacterial Spending-Market Forecast 2017-2027
    • 10.7.2. Action to Encourage Antibacterial Drug Development in the EU
    • 10.7.3. Italy Continues to Lead the Way in Antibiotic Use
    • 10.7.4. The French Fascination with Expensive Antibacterial Drugs
    • 10.7.5. Germany-Europe's Antibiotic Steward
    • 10.7.6. Rising Use of Antibacterials Drugs in the UK
    • 10.7.7. Spanish Antibacterials Market to Expand from 2021 to 2027
  • 10.8. Japan-Still the Fourth Largest National Market
    • 10.8.1. The Pause Before Growth in the Japanese Market
  • 10.9. Will South Korea Continue Its High Use of Antibiotics?
  • 10.10. BRIC Nation Sales Still Expanding-Market Forecast 2017-2027
  • 10.11. Chinese Antibacterial Market Bloated by Reported Overuse
    • 10.11.1. Developing Antibacterials in China, for China
    • 10.11.2. Governmental Controls Subdue Recent Growth-Market Forecast 2017-2027
  • 10.12. Indian Market to Expand by 50% Over the Forecast Period
    • 10.12.1. Restricting Antibiotic Use in India
    • 10.12.2. Sustained Expansion of the Indian Market, Forecast 2017-2027
  • 10.13. Brazilian Antibacterial Market to Double in Size
    • 10.13.1. Brazilian Market to Be Driven by Drug Resistance
    • 10.14. Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2017-2027

11. Antibacterials R&D Pipeline Review, 2017

  • 11.1. Gram-Positive vs. Gram-Negative
  • 11.2. Pipeline Dominated by Small Molecule Drugs
  • 11.3. Leading Phase III Pipeline Treatment Candidates
    • 11.3.1. Surotomycin-Broad C. difficile Treatment to Reduce Relapse
    • 11.3.2. Baxdela (delafloxacin)-A Leading pH Activated, Broad Spectrum Fluoroquinolone
    • 11.3.3. Solithera (solithromycin)-Fluroketolide with Favourable Side Effect Profile
    • 11.3.4. Eravacycline-Treating Gram-Negative cUTIs and cIAIs
    • 11.3.5. Plazomicin-Straight to PIII in Carbapenem Resistant Infections
    • 11.3.6. Omadacycline-Another Phase III-Ready Partnership
    • 11.3.7. Relebactam-A Novel β-Lactamase Combination
    • 11.3.8. CEM-102(Fusidic acid)-Cempra's Second Pipeline Candidate
    • 11.3.9. BC-3781- Unique Mechanism of Action at 23S?
  • 11.4. Leading Phase II Antibacterial Drug Candidates
    • 11.4.1. Radezolid-Apparently on Melinta's Back-Burner for Now
    • 11.4.2. AFN-1252: Highly Specific S. Aureus Antibacterial
    • 11.4.3. TD-1792-A Russian Antibacterial Medicine
    • 11.4.4. Brilacidin-A Novel Peptide Antibacterial Agent
  • 11.5. Inhaled Antibiotics-Advantages in Lung Infections
    • 11.5.1. Cayston: Competition for Novartis?
    • 11.5.2. ARIKACE-Targeting P. aeruginosa
    • 11.5.3. Aeroquin-Better than Podhaler?
    • 11.5.4. BAYQ3939-Developments for Cystic Fibrosis
    • 11.5.5. NKTR-061: Targeting Intubated Pneumonia
    • 11.5.6. Pulmaquin: A Second Ciprofloxacin Candidate
    • 11.5.7. AeroVanc Targets MRSA Infections
    • 11.5.8. Inhaled Amikacin-Fosfomycin-Adjunctive Therapy for VAP
  • 11.6. Biologics-Truly Novel Antibacterial Therapeutics
    • 11.6.1. MK-3415A: First Antibacterial mAb to the Market?
    • 11.6.2. KB001A-The Leading Antibody Against P. aeruginosa
    • 11.6.3. Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
    • 11.6.4. MEDI4893 - Early Stage mAb to S. Aureus
  • 11.7. Other Classes
    • 11.7.1. AZD0914-Novel DNA Gyrase Inhibitor
    • 11.7.2. MRX-I-Safer Oral Oxazolidinone to Treat MRSA
    • 11.7.3. GSK2140944-BTI Class of Antibiotics
    • 11.7.4. Carbavance-to Treat CRE

12. Qualitative Analysis of the Antibacterial Industry and Market, 2017

  • 12.1. SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
  • 12.2. STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
    • 12.2.1. Social Factors
    • 12.2.2. Technological Developments
    • 12.2.3. Economic Pressures
    • 12.2.4. Political Issues
  • 12.3. Market is Well Established and Demand Will Remain Strong
  • 12.4. High Prevalence of Bacterial Infection Worldwide
  • 12.5. Worldwide Demand for Antibacterials
  • 12.6. Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
  • 12.7. Cutting into a Saturated Market
  • 12.8. Superior Benefit over Generics?
  • 12.9. Resistance-Nature's Patent Expiry
  • 12.10. Acute Treatment Limits Commercial Potential
  • 12.11. Did Big Pharma Back Away from Antibacterial Drugs?
  • 12.12. Resistance Will Continue to Present New Targets
  • 12.13. First Biologic Antibacterials
  • 12.14. Potential for Smaller Firms to Capitalise
  • 12.15. Developing Preventative Vaccines Rather Than Treatments
  • 12.16. Antibacterial Stewardship Reduces Usage
  • 12.17. Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
    • 12.17.1. Therapeutic Success in European Clinical Trials
    • 12.17.2. Primary End Points in FDA Guidelines
  • 12.18. Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
  • 12.19. Enticing Antibacterial Drug Discovery-Push and Pull Incentives
    • 12.19.1. GAIN act: Post-Development Pull Incentives in the US
    • 12.19.2. ADAPT-Building on the GAIN act
    • 12.19.3. EMA Update Guideline-Streamlining Clinical Trials in the EU
    • 12.19.4. Push Incentives for Antibacterial Drug Discovery with Public Funding
    • 12.19.5. IMI: Public-Private Collaboration with GSK and AstraZeneca
    • 12.19.6. Public Finance Pumping Money into Antibacterial Development

13. Antibacterial Drugs Market 2017 - 2027: Conclusions

  • 13.1. Three Blockbuster Antibacterials in 2016 - Leading Brands
  • 13.2. The Leading Branded Antibacterial Drugs in 2027
  • 13.3. Signs of Life in the Antibacterial R&D Pipeline
  • 13.4. Stemming the Tide of Antibacterial Drug Resistance
  • 13.5. The Changing Face of Antibacterial Clinical Development

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: (Sample) Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2017-2027
  • Table 2.1: Common Bacterial Infections and Their Causes
  • Table 2.2: Details of the ESKAPE Bacteria
  • Table 2.3: Leading Causes of Infectious Diseases Deaths Worldwide, 2010
  • Table 2.4: Mechanisms of Action for Antibacterial Drugs
  • Table 3.1: Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2011-2016
  • Table 3.2: Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2016
  • Table 3.3: Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2017-2027
  • Table 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2017-2027
  • Table 3.5: Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2016
  • Table 4.1: Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
  • Table 4.2: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2016
  • Table 4.3: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 4.4: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2027
  • Table 4.5: Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.6: Cephalosporin Market Forecast by Product: Market Share (%), 2017-2027
  • Table 4.7: Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.8: Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.9: Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.10: Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.11: Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.12: Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
  • Table 4.13: Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.14: Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.15: Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 4.16: Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.1: Leading Branded Penicillin Drugs: Important Facts
  • Table 5.2: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2016
  • Table 5.3: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2021
  • Table 5.4: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2027
  • Table 5.5: Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.6: Penicillin Market Forecast by Product: Market Share (%), 2017-2027
  • Table 5.7: Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.8: Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.9: Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.10: Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.11: Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 5.12: Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.1: Leading Branded Fluoroquinolone Drugs: Important Facts
  • Table 6.2: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2016
  • Table 6.3: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 6.4: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2027
  • Table 6.5: Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.6: Fluoroquinolone Market Forecast by Product: Market Share (%), 2017-2027
  • Table 6.7: Global Patent Expiration Dates for Avelox
  • Table 6.8: Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.9: Generic Manufacturers of Levofloxacin, 2016
  • Table 6.10: Cravit and Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.11: Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.12: Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.13: Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.14: Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 6.15: Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.1: Leading Branded Macrolides: Important Facts
  • Table 7.2: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2016
  • Table 7.3: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 7.4: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2027
  • Table 7.5: Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.6: Macrolide Market Forecast by Product: Market Shares (%), 2017-2027
  • Table 7.7: Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.8: Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.9: Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.10: Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 7.11: Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 8.1: Leading Branded Carbapenems: Important Facts
  • Table 8.2: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2016
  • Table 8.3: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 8.4: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2027
  • Table 8.5: Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 8.6: Carbapenem Market Forecast by Product: Market Share (%), 2017-2027
  • Table 8.7: Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 8.8: Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 8.9: Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 8.10: Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.1: Other Leading Branded Antibacterials: Important Facts
  • Table 9.2: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2016
  • Table 9.3: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 9.4: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2027
  • Table 9.5: Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.6: Other Agents: Market Forecast by Product - Market Share (%), 2017-2027
  • Table 9.7: Oxazolidinones in Mid to Late Stage Clinical Development, 2016
  • Table 9.8: Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.9: Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.10: Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.11: TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.12: Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.13: Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.14: Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.15: Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.16: Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.17: Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.18: Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 9.19: Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.1: Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2016
  • Table 10.2: Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2017-2027
  • Table 10.3: Antibacterial Drug Markets: National and Regional Market Shares (%), 2017-2027
  • Table 10.4: Incidence of Pneumonia in National Markets, 2016
  • Table 10.5: Incidence of Community Acquired Urinary Tract Infections in National Markets, 2016
  • Table 10.6: Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2016
  • Table 10.7: Incidence of Upper Respiratory Tract Infections in National Markets, 2016
  • Table 10.8: Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
  • Table 10.9: Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
  • Table 10.10: US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.11: EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.12: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.13: French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.14: German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.15: UK Early Stage Antibacterial Drug Developers, 2016
  • Table 10.16: UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.17: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.18: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.19: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.20: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.21: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.22: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.23: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 10.24: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
  • Table 11.1: Small Molecule Antibacterial Drug in Phase III Development, 2016
  • Table 11.2: Small Molecule Antibacterial Drug in Phase II Development, 2016
  • Table 11.3: Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical Development, 2016
  • Table 11.4: Biological Antibacterial Therapeutics in Clinical Development, 2016
  • Table 12.1: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2017-2027
  • Table 12.2: Bacterial Related Funding for BARDA, 2011-2014
  • Table 13.1: World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2016, 2021 and 2027

List of Figures

  • Figure 2.1: Leading Causes of Infectious Disease Deaths Worldwide, 2010
  • Figure 2.2: Key Events in the History of Antibacterial Drug Development
  • Figure 3.1: Historic Global Market Size ($bn), 2011-2016
  • Figure 3.2: Global Antibacterial Drug Market by Sector: Market Share (%), 2016
  • Figure 3.3: Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2017-2027
  • Figure 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2021
  • Figure 3.5: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2027
  • Figure 3.6: Ten Leading Branded Antibacterial Manufacturers: Market Share (%), 2016
  • Figure 4.1: Cephalosporin Market by Product: Market Share (%), 2016
  • Figure 4.2: Cephalosporin Market by Product: Market Share (%), 2021
  • Figure 4.3: Cephalosporin Market by Product: Market Share (%), 2027
  • Figure 4.4: Cephalosporin Market Forecast: Revenue ($bn), 2017-2027
  • Figure 4.5: Cephalosporin Market: Drivers and Restraints, 2017-2027
  • Figure 4.6: Rocephin Forecast: Revenue ($bn), 2017-2027
  • Figure 4.7: Sulperazon Forecast: Revenue ($bn), 2017-2027
  • Figure 4.8: Zinnat/Ceftin Forecast: Revenue ($bn), 2017-2027
  • Figure 4.9: Meiact Forecast: Revenue ($bn), 2017-2027
  • Figure 4.10: Flomox Forecast: Revenue ($bn), 2017-2027
  • Figure 4.11: Zinforo/Teflaro Forecast: Revenue ($bn), 2017-2027
  • Figure 4.12: Zeftera Forecast: Revenue ($bn), 2017-2027
  • Figure 4.13: Ceftolozane-Tazobactam Forecast: Revenue ($bn), 2017-2027
  • Figure 4.14: Ceftazidime-Avibactam Forecast: Revenue ($bn), 2017-2027
  • Figure 5.1: Penicillin Market by Product: Market Share (%), 2016
  • Figure 5.2: Penicillin Market by Product: Market Share (%), 2021
  • Figure 5.3: Penicillin Market by Product: Market Share (%), 2027
  • Figure 5.4: Penicillin Market Forecast: Revenue ($bn), 2017-2027
  • Figure 5.5: Augmentin Forecast: Revenue ($bn), 2017-2027
  • Figure 5.6: Zosyn/Tazocin Forecast: Revenue ($bn), 2017-2027
  • Figure 5.7: Unasyn Forecast: Revenue ($bn), 2017-2027
  • Figure 5.8: Amoxil Forecast: Revenue ($bn), 2017-2027
  • Figure 5.9: Generic Amoxicillin Forecast: Revenue ($bn), 2017-2027
  • Figure 5.10: Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2017-2027
  • Figure 6.1: Fluoroquinolone Market by Product: Market Share (%), 2016
  • Figure 6.2: Fluoroquinolone Market by Product: Market Share (%), 2021
  • Figure 6.3: Fluoroquinolone Market by Product: Market Share (%), 2027
  • Figure 6.4: Fluoroquinolone Market Forecast: Revenue ($bn), 2017-2027
  • Figure 6.5: Avelox Forecast: Revenue ($bn), 2017-2027
  • Figure 6.6: Cravit and Levaquin Forecast: Revenue ($bn), 2017-2027
  • Figure 6.7: Vigamox Forecast: Revenue ($bn), 2017-2027
  • Figure 6.8: Ciprodex Forecast: Revenue ($bn), 2017-2027
  • Figure 6.9: Cipro/Ciprobay Forecast: Revenue ($bn), 2017-2027
  • Figure 6.10: Geninax Forecast: Revenue ($bn), 2017-2027
  • Figure 6.11: Delafloxacin Forecast: Revenue ($bn), 2017-2027
  • Figure 7.1: Macrolide Market by Product: Market Share (%), 2016
  • Figure 7.2: Macrolide Market by Product: Market Share (%), 2021
  • Figure 7.3: Macrolide Market by Product: Market Share (%), 2027
  • Figure 7.4: Macrolide Market Forecast: Revenue ($bn), 2017-2027
  • Figure 7.5: Biaxin/Clarith Forecast: Revenue ($bn), 2017-2027
  • Figure 7.6: Zithromax Forecast: Revenue ($bn), 2017-2027
  • Figure 7.7: Dalacin Forecast: Revenue ($bn), 2017-2027
  • Figure 7.8: Dificid Forecast: Revenue ($bn), 2017-2027
  • Figure 7.9: Solithromycin Forecast: Revenue ($bn), 2017-2027
  • Figure 8.1: Carbapenem Market by Product: Market Share (%), 2016
  • Figure 8.2: Carbapenem Market by Product: Market Share (%), 2021
  • Figure 8.3: Carbapenem Market by Product: Market Share (%), 2027
  • Figure 8.4: Carbapenem Market Forecast: Revenue ($bn), 2017-2027
  • Figure 8.5: Merrem Forecast: Revenue ($bn), 2017-2027
  • Figure 8.6: Primaxin Forecast: Revenue ($bn), 2017-2027
  • Figure 8.7: Invanz Forecast: Revenue ($bn), 2017-2027
  • Figure 8.8: Doribax Forecast: Revenue ($bn), 2017-2027
  • Figure 9.1: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2016
  • Figure 9.2: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2021
  • Figure 9.3: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2027
  • Figure 9.4: Other Agents Market Forecast by Product: Revenue ($bn), 2017-2027
  • Figure 9.5: Zyvox Forecast: Revenue ($bn), 2017-2027
  • Figure 9.6: Cubicin Forecast: Revenue ($bn), 2017-2027
  • Figure 9.7: Tygacil Forecast: Revenue ($bn), 2017-2027
  • Figure 9.8: TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2017-2027
  • Figure 9.9: Solodyn Forecast: Revenue ($bn), 2017-2027
  • Figure 9.10: Vibativ Forecast: Revenue ($bn), 2017-2027
  • Figure 9.11: Sirturo Forecast: Revenue ($bn), 2017-2027
  • Figure 9.12: Tedizolid Forecast: Revenue ($bn), 2017-2027
  • Figure 9.13: Oritavancin Forecast: Revenue ($bn), 2017-2027
  • Figure 9.14: Dalbavancin Forecast: Revenue ($bn), 2017-2027
  • Figure 9.15: Surotomycin Forecast: Revenue ($bn), 2017-2027
  • Figure 9.16: Nemonoxacin Forecast: Revenue ($bn), 2017-2027
  • Figure 10.1: Antibacterial Drug Sales by National and Regional Markets: Market Share (%), 2016
  • Figure 10.2: Antibacterial Drug Market Forecasts: National and Regional Market Sizes ($bn), 2017-2027
  • Figure 10.3: Absolute Annual Antibacterial Drug Consumption by Nation, 2016
  • Figure 10.4: Per Capita Antibacterial Drug Consumption by Nation, 2016
  • Figure 10.5: US Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.6: EU Antibacterial Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2017-2027
  • Figure 10.7: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.8: French Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.9: German Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.10: UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.11: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.12: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.13: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.14: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), 2017-2027
  • Figure 10.15: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.16: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.17: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 10.18: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
  • Figure 12.1: Strengths and Weaknesses of the Antibacterial Drug Market, 2017-2027
  • Figure 12.2: Opportunities and Threats for the Antibacterial Drug Market, 2017-2027
  • Figure 12.3: Strategies and Technologies to Prevent Hospital Acquired Infections, 2016

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Achaogen
  • Actavis
  • Actelion
  • Affinium Pharmaceutical
  • AiCuris GmbH & Co. KG
  • Alcon
  • Alkem Laboratories
  • Allergan
  • Allied Pharma
  • Apotex
  • APP Pharmaceuticals
  • Aptalis Pharma
  • Aquapharm Biodiscovery
  • Aradigm
  • Aridis Pharmaceuticals
  • Ascend Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Pharmaceuticals
  • Basilea Pharmaceuticals
  • Bayer Laboratories
  • Biomax Biotechnics
  • Bristol-Myers Squibb
  • Cadila Healthcare
  • Calixa Therapeutics
  • Cardeas Pharma
  • Cellceutix
  • Cempra Pharmaceuticals
  • Cipla
  • Claris Lifesciences
  • Cornerstone Biopharma
  • Cornerstone Therapeutics
  • Corona Remedies
  • Critical Therapeutics
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Discuva
  • Dr. Reddy's Laboratories
  • Durata Therapeutics
  • Eli Lilly
  • Emcure Pharmaceuticals
  • Eros Pharma
  • Forest Laboratories
  • Furiex Pharmaceuticals
  • Gate Pharma
  • Gilead Sciences
  • Glenmark
  • GlycoVaxyn
  • GlaxoSmithKline (GSK)
  • Hetero
  • Hi-Tech Pharma
  • Hikma Farmaceutica
  • Hospira
  • Insmed
  • Intercell
  • Itochu Chemical Frontier
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • KaloBios
  • Kenta Biotech
  • Kuhnil Pharm
  • Lupin
  • Macleod Pharmaceuticals
  • Medicis
  • MedImmune
  • Meiji
  • Melinta Therapeutics
  • Merck & Co.
  • Merlion Pharmaceuticals
  • Microlabs
  • MicuRx Pharmaceuticals
  • Mpex Pharmaceuticals
  • Mylan
  • Nabriva Therapeutics
  • Nalneva
  • Neiss Labs
  • Nektar Therapeutics
  • Novacta Biosystems
  • Novartis
  • Novexel
  • Optimer Biotechnology
  • Orchid Chemicals
  • Orchid Healthcare
  • Ortho-McNeil
  • Paratek Pharmaceuticals
  • Peninsula Pharmaceuticals
  • Pfizer
  • Pharmacia
  • Phico Therapeutics
  • Piramal Healthcare
  • Plenus Pharmaceuticals
  • Pliva
  • Polyphor
  • Procarta Biosystems
  • Procter & Gamble Pharmaceuticals
  • Ranbaxy
  • Redx Pharma
  • Roche
  • Roxane
  • R-Pharma
  • Sagent Pharmaceuticals
  • Sandoz
  • Sanofi
  • Savara Pharmaceuticals
  • Sawai Pharmaceutical
  • Schering Plough
  • Seika Pharma
  • Sequella
  • Shanghai MengKe Pharmaceuticals
  • Shionogi
  • Shire
  • Sidmak Labs
  • Solitaire Pharmacia
  • Specialised Therapeutics Australia
  • Sunovion Pharma
  • TaiGen Biotechnology
  • Taisho Toyama
  • Takeda
  • TAP Holdings
  • Targanta Therapeutics
  • Tetraphase Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theravance
  • Torrent Pharmaceuticals
  • Trius Therapeutics
  • TTY Biopharma
  • Unichem Laboratories
  • Valeant Pharmaceuticals
  • Vansen Pharma
  • ViroPharma
  • Warner Chilcott
  • Watson
  • Wockhardt
  • Zhejiang Medicine Company
  • Zuellig Pharma
  • Zydus Pharmaceuticals

Organisations Mentioned

  • Agência Nacional de Vigil&qcirc;ncia Sanitária (ANVISA)
  • Duke University
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA)
  • Ministry of Health, Labour and Welfare (MHLW)
  • Michigan State University
  • National Institute for Health and Clinical Excellence (NICE)
  • National Institutes of Health (NIH)
  • University of Connecticut
  • World Health Organization (WHO)
Back to Top